# SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

> **NCT03552549** · PHASE2,PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 126 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** PEG-Intron
- **BIOLOGICAL:** INTRON A

## Key facts

- **NCT ID:** NCT03552549
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-08-05
- **Primary completion:** 2001-02-19
- **Final completion:** 2001-02-19
- **Target enrollment:** 126 (ACTUAL)
- **Why stopped:** This study was closed to enrollment prematurely due to sub-optimal accrual.
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552549, "SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03552549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*